Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 1,601–1,700 of 4,275
Senescent cells at the crossroads of aging, disease, and tissue homeostasis
Kuehnemann, C., & Wiley, C. D. (2023) · Aging Cell · doi:10.1111/acel.13988 · Cited by 50
“Alternatively, since senescence and the SASP can vary by cell type and inducer (Basisty et al., 2020; Coppe et al., 2008; Wiley et al., 2016), it may be the case that induction of senescence by mac-ronutrient stressors drives a specific secretome that promotes insulin resistance.”
BackgroundSimoncini, S., Château, A.-L., Robert, S., Todorova, D., Yzydorzick, C., Lacroix, R., Ligi, I., Louis, L., Bachelier, R., Siméoni, U., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08883-1 · Cited by 43
Cellular senescence in ischemia/reperfusion injury
Chen, C., Zheng, M., Hou, H., Fang, S., Chen, L., Yang, J., Yao, W., Zhang, Q., & Hei, Z. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01205-z · Cited by 44
Induction and transmission of oncogene-induced senescence
Rattanavirotkul, N., Kirschner, K., & Chandra, T. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03638-0 · Cited by 43
Hodjat, M., Haller, H. G., Dumler, I., & Kiyan, Y. (2012) · Journal of Vascular Research · doi:10.1159/000343000 · Cited by 38
Nair, R. R., Bagheri, M., & Saini, D. K. (2015) · Journal of Cell Science · doi:10.1242/jcs.159517 · Cited by 38
“…as reported previously (Masterson and O’Dea, 2007; Eriko et al., 1999; Suzuki et al., 2001), and that they are positive for SA-b-gal and show enhanced secretion of IL8 (Cho et al., 2011), which is similar to what is observed in senescent cells generated by other approaches (Coppé et al., 2008).”
BackgroundInfluentialDistinct senotypes in p16- and p21-positive cells across human and mouse aging tissues
Saul, D., Jurk, D., Doolittle, M. L., Kosinsky, R. L., Han, Y., Zhang, X., Franco, A. C., Kim, S. Y., Wyles, S. P., Prakash, Y. S., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00601-2 · Cited by 45
“Similarly, IGFBP4 and IGFBP6 show increased levels in aging tissues and senescent cells (Coppé et al, 2008; Moiseeva et al, 2023), while EDN1 (Endothelin-1) expression increases in senescent vascular cells (Alcalde-Estévez et al, 2020).”
Conte, T. C., Duran-Bishop, G., Orfi, Z., Mokhtari, I., Deprez, A., Côté, I., Molina, T., Taeyeon, K., Tellier, L., Roussel, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39663-3 · Cited by 47
“This cocktail, known as the Senescence-Associated Secretory Pheno-type (SASP), alters the microenvironment and leads to detrimental changes in neighboring cells and in the whole organism 15,16 .”
Sundar, I. K., Rashid, K., Gerloff, J., Rangel‐Moreno, J., Li, D., & Rahman, I. (2018) · The FASEB Journal · doi:10.1096/fj.201701518r · Cited by 38
“The hallmark of senescent cells includes proliferation arrest (no cell division), very high metabolic activity, and enlarged cell phenotype associated with secretory phenotype (release of cytokines, chemokines, growth factors, and matrix metalloproteases), which are collectively referred to as SASP (36).”
BackgroundGil, T., Zheng, H., Lee, H. G., Shin, J.-W., Hwang, S. W., Jang, K.-M., & Jeon, O. H. (2022) · Aging · doi:10.18632/aging.204204 · Cited by 49
“com 6007 AGING pro-inflammatory molecules termed senescenceassociated secretory phenotypes (SASP), which can induce structural and functional changes in the surrounding cells and tissues [4].”
BackgroundGorwood, J., Ejlalmanesh, T., Bourgeois, C., Mantecon, M., Rose, C., Atlan, M., Desjardins, D., Grand, R. L., Fève, B., Lambotte, O., et al. (2020) · Cells · doi:10.3390/cells9040854 · Cited by 41
“Tat- or Nef-treated ASCs displayed signs of SASP, with greater secretion of the pro-inflammatory cytokines IL-6 and IL-8 (Figure 3A,B).”
BackgroundInfluentialMedicinal chemistry perspective on cGAS-STING signaling pathway with small molecule inhibitors
Tian, X., Xu, F., Zhu, Q., Feng, Z., Dai, W., Zhou, Y.-L., You, Q., & Xu, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114791 · Cited by 44
A role for cellular senescence in birth timing
Cha, J. M., & Aronoff, D. M. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1371888 · Cited by 42
“constitutents of the TGFb, IGF, and VEGF signaling pathways.(18,60) Recently, attention has also been focused on extracel-”
BackgroundKim, S. B., Bozeman, R., Kaisani, A. A., Kim, W., Zhang, L., Richardson, J. A., Wright, W. E., & Shay, J. W. (2015) · Oncogene · doi:10.1038/onc.2015.395 · Cited by 38
Age and metastasis – How age influences metastatic spread in cancer. Colorectal cancer as a model
Pretzsch, E., Nieß, H., Bösch, F., Westphalen, C. B., Jacob, S., Neumann, J. H. L., Werner, J., Heinemann, V., & Angele, M. K. (2022) · Cancer Epidemiology · doi:10.1016/j.canep.2022.102112 · Cited by 41
Kuba, A., & Raida, L. (2018) · Mediators of Inflammation · doi:10.1155/2018/9451950 · Cited by 45
“Additional inflammatory cytokines such as the colony-stimulating factors (GM-CSF and GCSF) are secreted at high levels by senescent fibroblasts [86].”
BackgroundGoing with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology
Xie, H., Appelt, J. W., & Jenkins, R. W. (2021) · Cancers · doi:10.3390/cancers13236052 · Cited by 42
Celli, B. R. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201107-039ms · Cited by 38
Wilhelmsen, A., Tsintzas, K., & Jones, S. W. (2021) · GeroScience · doi:10.1007/s11357-021-00322-4 · Cited by 42
Hu, L., Dong, C., Wang, Z., He, S., Yang, Y., Zi, M., Li, H., Zhang, Y., Chen, C., Zheng, R., et al. (2023) · Aging Cell · doi:10.1111/acel.13896 · Cited by 43
“Likewise, the upregulation of various SASP components depends on cell type (Coppé et al., 2008).”
BackgroundThe impact of ageing mechanisms on musculoskeletal system diseases in the elderly
Cai, Y., Han, Z., Cheng, H., Li, H., Wang, K., Chen, J., Liu, Z., Xie, Y., Lin, Y., Zhou, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1405621 · Cited by 57
p53 and rapamycin are additive
Christy, B., Demaria, M., Campisi, J., Huang, J., Jones, D., Dodds, S. G., Williams, C., Hubbard, G., Livi, C. B., Gao, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4602 · Cited by 37
“Human primary fibroblasts were exposed to 10 Gy X-ray or mock irradiation, as previously described [38].”
BackgroundMethodSelf-citationCellular Senescence in Immunity against Infections
Marrella, V., Facoetti, A., & Cassani, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911845 · Cited by 44
“In addition, SnCs secrete chemokines, cytokines, metalloproteases, reactive oxygen species (ROS), metabolites, miRNAs and extracellular vesicles in a complex defined as the senescent secretory phenotype (SASP) [2,3].”
BackgroundThe danger signal plus DNA damage two-hit hypothesis for chronic inflammation in COPD
Aoshiba, K., Tsuji, T., Yamaguchi, K., Itoh, M., & Nakamura, H. (2013) · European Respiratory Journal · doi:10.1183/09031936.00102912 · Cited by 39
SIPS as a model to study age-related changes in proteolysis and aggregate formation
Ott, C., Jung, T., Grune, T., & Höhn, A. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.07.007 · Cited by 44
The Emerging Role of Senotherapy in Cancer: A Comprehensive Review
Malayaperumal, S., Marotta, F., Kumar, M. M., Somasundaram, I., Ayala, A., Pinto, M. F. M., Banerjee, A., & Pathak, S. (2023) · Clinics and Practice · doi:10.3390/clinpract13040076 · Cited by 41
“An extensive range of proteins, such as inflamma-tory cytokines, growth factors, cyclooxygenase, chemokines, and metalloproteinase, are secreted by these cells [3,14].”
BackgroundAzimzadeh, O., Moertl, S., Ramadan, R., Baselet, B., Laiakis, E. C., Sebastian, S., Beaton, D., Hartikainen, J. M., Kaiser, J. C., Beheshti, A., et al. (2022) · International Journal of Radiation Biology · doi:10.1080/09553002.2022.2110325 · Cited by 40
“This senescenceassociated secretory phenotype (SASP) can contribute to different cellular responses (Coppe et al. 2008).”
BackgroundRitchie, S., Reed, D. A., Pereira, B., & Timpson, P. (2021) · Faculty Reviews · doi:10.12703/r/10-4 · Cited by 47
Gleason, C. E., Dickson, M. A., Klein, M. E., Antonescu, C. R., Gularte‐Mérida, R., Benitez, M., Delgado, J. I., Kataru, R. P., Tan, M. W. Y., Bradić, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2378 · Cited by 42
Prince, E. W., Apps, J. R., Jeang, J., Chee, K., Medlin, S., Jackson, E. M., Dudley, R., Limbrick, D. D., Naftel, R. P., Johnston, J. M., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae015 · Cited by 48
Fibroblast activation and senescence in oral cancer
Prime, S. S., Cirillo, N., Hassona, Y. M., Lambert, D., Paterson, I. C., Mellone, M., Thomas, G. J., James, E. N., & Parkinson, E. K. (2016) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12456 · Cited by 42
Schwarzenbach, C., Tatsch, L., Vilar, J. B., Rasenberger, B., Beltzig, L., Kaina, B., Tomicic, M. T., & Christmann, M. (2021) · Cancers · doi:10.3390/cancers13143585 · Cited by 42
Cancer-associated fibroblasts in radiotherapy: Bystanders or protagonists?
Martínez-Zubiaurre, I., & Hellevik, T. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01093-5 · Cited by 40
“On the other hand, the presence of senescent cells in the tumor stroma or its surroundings can aid in the establishment of an immunosuppressive [64, 65], pro-angiogenic [66], pro-inflammatory and catabolic microenvironment [33, 67, 68] that stimulate tumor growth and cancer cell dissemination.”
BackgroundTargeting cellular senescence in cancer by plant secondary metabolites: A systematic review
Fakhri, S., Moradi, S. Z., Ash-Rafzadeh, A., & Bishayee, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105961 · Cited by 39
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome
Michelotti, A., de Scordilli, M., Palmero, L., Guardascione, M., Masala, M., Roncato, R., Foltran, L., Ongaro, E., & Puglisi, F. (2021) · Cells · doi:10.3390/cells10082034 · Cited by 48
“Moreover, the increased enterohepatic circulation of DCA causes functional changes in hepatic stellate cells, which adopt a senescence-associated secretory phenotype (SASP) [71] due to chronic stress (DCA is a known DNA damaging agent through ROS production) [72].”
BackgroundDynamic regulation of myofibroblast phenotype in cellular senescence
López‐Antona, I., Contreras‐Jurado, C., Luque‐Martín, L., Carpintero‐Leyva, A., González‐Méndez, P., & Palmero, I. (2022) · Aging Cell · doi:10.1111/acel.13580 · Cited by 40
The Interaction of miR-378i-Skp2 Regulates Cell Senescence in Diabetic Nephropathy
Tsai, Y., Kuo, P., Kuo, M., Hung, W., Wu, L., Chang, W., Wu, P., Lee, S., Chen, H., & Hsu, Y. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120468 · Cited by 38
“Additionally, senescent cells are highly active metabolically, whereby they develop a multi-component senescence-associated secretory phenotype (SASP), such as interleukin-6 (IL-6), IL-8, and monocyte chemoattractant protein-1 (MCP-1) [8,9], which contains transcriptional activation and numerous secretory factors that…”
BackgroundLim, H. A., Park, B. K., Shin, S. Y., Kwon, Y. S., & Kim, H. P. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0909-y · Cited by 39
“Recently, it has been found that senescence cells express senescence-associated secretory phenotype (SASP) released to the surrounding environment (Coppé et al. 2008, 2010).”
Backgroundkar, B., Liu, B., Zhou, Z., & Lam, Y. W. (2011) · BMC Cell Biology · doi:10.1186/1471-2121-12-33 · Cited by 41
“Senescence can be accelerated by subjecting cultured cells to chemical or genotoxic stress, such as sodium butyrate [3,4], MTX [5], irradiation [6,7] or by overexpressing the oncogenic ras gene [8].”
BackgroundThe Hardest Part: Arterial Stiffness in the Context of Healthy Aging
Schellinger, I. N., Mattern, K., & Raaz, U. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311578 · Cited by 42
Zhang, R., Zhu, Z., Ma, Y., Tang, T., Wu, J., Huang, F., Xu, L., Wang, Y., & Zhou, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155629 · Cited by 41
Senescence and pre-malignancy: How do tumors progress?
Saab, R. H. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.09.013 · Cited by 42
Cellular senescence signaling in cancer: A novel therapeutic target to combat human malignancies
Fakhri, S., Moradi, S. Z., DeLiberto, L. K., & Bishayee, A. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114989 · Cited by 42
Epigenetic dysregulation in cardiovascular aging and disease
Herman, A. B., Occean, J. R., & Sen, P. (2021) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2021.16 · Cited by 46
“Senescent cells were discovered in 1965 by Hayflick[16] as cells with a limited proliferative capacity; however, we now define senescence as those cells with indefinite cell cycle arrest, resistance to apoptosis, and expression of a senescence associated secretory phenotype (SASP)[17].”
BackgroundInfluentialAlerting the immune system to DNA damage: micronuclei as mediators
MacDonald, K. M., Benguerfi, S., & Harding, S. M. (2020) · Essays in Biochemistry · doi:10.1042/ebc20200016 · Cited by 43
Solovyeva, E. M., Ibebunjo, C., Utzinger, S., Eash, J. K., Dunbar, A., Naumann, U., Zhang, Y., Serluca, F. C., Demirci, S., Oberhauser, B., et al. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111510 · Cited by 38
“Replicative senescence is mainly driven by p16 (Coppé et al., 2008; Campisi, 2013; Childs et al., 2015; He and Sharpless, 2017; Herranz and Gil, 2018).”
Mazzucco, A. E., Smogorzewska, A., Kang, C., Luo, J., Schlabach, M. R., Xu, Q., Patel, R., & Elledge, S. J. (2017) · Genes & Development · doi:10.1101/gad.304857.117 · Cited by 35
New insights into oncogenic stress
Haigis, K. M., & Sweet-Cordero, A. (2011) · Nature Genetics · doi:10.1038/ng0311-177 · Cited by 42
Wang, Y., Wang, Y., Yang, M., & Ma, X. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111191 · Cited by 34
Senescence Induced by UVB in Keratinocytes Impairs Amino Acids Balance
Bauwens, É., Parée, T., Meurant, S., Bouriez, I., Hannart, C., Wéra, A.-C., Khelfi, A., Fattaccioli, A., Burteau, S., Demazy, C., et al. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.11.017 · Cited by 41
Zhao, Y., Wu, Z., Chanal, M., Guillaumond, F., Goehrig, D., Bachy, S., Principe, M., Ziverec, A., Flaman, J., Collin, G., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3763 · Cited by 40
IER2-induced senescence drives melanoma invasion through osteopontin
Kyjacová, L., Saup, R., Rönsch, K., Wallbaum, S., Dukowic‐Schulze, S., Foss, A., Scherer, S. D., Rothley, M., Neeb, A., Grau, N., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02027-6 · Cited by 39
Insights into the role of senescence in tumor dormancy: mechanisms and applications
DeLuca, V. J., & Saleh, T. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10082-6 · Cited by 40
“1 3 demonstrated as having up to 40% senescent cells; this includes studies on patient samples derived from breast cancer patients treated with doxorubicin and cyclophosphamide [41], prostate cancer patients treated with mitoxantrone [42] or androgen deprivation [43], colorectal cancer patients after receiving 5-fluor…”
BackgroundReplication Stress: A Lifetime of Epigenetic Change
Khurana, S., & Oberdoerffer, P. (2015) · Genes · doi:10.3390/genes6030858 · Cited by 39
“Notably, senescence can trigger the aberrant secretion of cytokines, a feature termed senescence-associated secretory phenotype (SASP), which has been linked to both chronic inflammatory diseases and cancer [27–31].”
BackgroundAlharbi, K. S., Afzal, O., Altamimi, A. S. A., Almalki, W. H., Kazmi, I. A., Al-Abbasi, F. A., Alzarea, S. I., Makeen, H. A., & Albratty, M. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14471 · Cited by 37
Hu, Y., Zhao, Y., Li, P., Lu, H., Li, H., & Ge, J. (2023) · 中国科学通报:英文版 · doi:10.1016/j.scib.2023.07.032 · Cited by 41
Placental Senescence and the Two‐Stage Model of Preeclampsia
Sugulle, M., Fiskå, B. S., Jacobsen, D. P., Fjeldstad, H. E., & Staff, A. C. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.13904 · Cited by 49
Laine, A., & Westermarck, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1942 · Cited by 36
Biomarkers in the path from cellular senescence to frailty
Zampino, M., Ferrucci, L., & Semba, R. D. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110750 · Cited by 42
O’Hara, S. P., Splinter, P. L., Trussoni, C. E., Pisarello, M. J. L., Loarca, L., Splinter, N. S., Schutte, B. F., & LaRusso, N. F. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.777409 · Cited by 36
“In recent work, we demonstrated that senescent cholangiocytes are abundant in PSC livers, and these senescent cells exhibit characteristics of the senescence-associated secretory phenotype (SASP) (11), a potentially pathologic state of proinflammatory cytokine, chemokine, and growth factor hypersecretion (12).”
BackgroundFriend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging
Coder, B., Wang, W., Wang, L., Wu, Z., Zhuge, Q., & Su, D.-M. (2017) · Oncotarget · doi:10.18632/oncotarget.12572 · Cited by 36
Vandenberk, B., Brouwers, B. A. H., Hatse, S., & Wildiers, H. P. M. W. (2011) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2011.08.004 · Cited by 40
Applications of Protein Microarrays in Biomarker Discovery for Autoimmune Diseases
Li, S., Song, G., Bai, Y., Song, N., Zhao, J., Liu, J., & Hu, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645632 · Cited by 47
Guillon, J., Coquelet, H., Leman, G., Toutain, B., Petit, C., Henry, C., Boissard, A., Guette, C., & Coqueret, O. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009953 · Cited by 36
“Initially described as beneficial, several studies have reported that its composition varies and that this secretome can also enhance inflammation or tumor progression (11-13).”
Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies
Daenen, L. G. M., Houthuijzen, J. M., Cirkel, G. A., Roodhart, J. M. L., Shaked, Y., & Voest, E. E. (2013) · Oncogene · doi:10.1038/onc.2013.94 · Cited by 41
Zou, X., Zou, D., Li, L., Yu, R., Li, X., Du, X.-Y., Guo, J., Wang, K., & Liu, W. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03137-y · Cited by 42
“Chronic inflammation is a key mechanism for ageing-related diseases [18].”
BackgroundKomatsu, T., Park, S., Hayashi, H., Mori, R., Yamaza, H., & Shimokawa, I. (2019) · Nutrients · doi:10.3390/nu11123068 · Cited by 43
“This phenomenon is called the senescence-accelerated secretory phenotype (SASP) [27].”
BackgroundInfluentialA geroscience motivated approach to treat Alzheimer’s disease: Senolytics move to clinical trials
Gonzales, M. M., Krishnamurthy, S., Garbarino, V. R., Daeihagh, A. S., Gillispie, G. J., Deep, G., Craft, S., & Orr, M. E. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111589 · Cited by 38
Haydont, V., Neiveyans, V., Fortunel, N. O., & Asselineau, D. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.01.003 · Cited by 36
Qiao, W., Yu, S., Sun, H., Chen, L., Wang, R., Wu, X., Goltzman, D., & Miao, D. (2020) · PubMed · Cited by 43
Dobbelstein, M., & Levine, A. J. (2020) · Cancer Science · doi:10.1111/cas.14433 · Cited by 37
Song, Z., Zhang, J., Ju, Z., & Rudolph, K. L. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00802.x · Cited by 36
“Recent studies showed that senescence changes the secretome of cells exhibiting cell proliferation stimulating activity (Coppe et al., 2008).”
BackgroundVétillard, A., Jonchère, B., Moreau, M., Toutain, B., Henry, C., Fontanel, S., Bernard, A.-C., Campone, M., Guette, C., & Coqueret, O. (2015) · Oncotarget · doi:10.18632/oncotarget.6126 · Cited by 36
Tissue engineering strategies to bioengineer the ageing skin phenotype in vitro
Costello, L., DiColandrea, T., Tasseff, R. A., Isfort, R. J., Bascom, C., von Zglinicki, T., & Przyborski, S. A. (2022) · Aging Cell · doi:10.1111/acel.13550 · Cited by 35
cGAS and cancer therapy: a double-edged sword
Du, J., Qian, M., Yuan, T., Chen, R., He, Q., Yang, B., Ling, Q., & Zhu, H. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00839-6 · Cited by 45
“In contrast to the acute cGASinduced SASP, the cGAS-STING signaling pathway is continuously activated at a low intensity, resulting in a large accumulation of IL6 and other SASP molecules, which will induce the invasiveness of epithelial cells, transformation, and metastasis and promote tumor angiogenesis together wit…”
BackgroundSenopathies-Diseases Associated with Cellular Senescence
Lushchak, O., Schosserer, M., & Grillari, J. (2023) · Biomolecules · doi:10.3390/biom13060966 · Cited by 35
“The SASP is considered the main trigger of tissue damage caused by SCs and is composed of pro-inflammatory cytokines, chemokines, and matrix-remodeling factors [22].”
Backgroundp53 regulated senescence mechanism and role of its modulators in age-related disorders
Pawge, G., & Khatik, G. L. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114651 · Cited by 44
Sav1 Loss Induces Senescence and Stat3 Activation Coinciding with Tubulointerstitial Fibrosis
Leung, J. Y., Wilson, H. L., Voltzke, K. J., Williams, L. A., Lee, H. J., Wobker, S. E., & Kim, W. Y. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00565-16 · Cited by 38
“cells have been shown to have deleterious effects on organisms by contributing to age-related pathology through inducing expression of genes associated with senescenceassociated secretory phenotypes (SASPs), including genes encoding interleukins, chemokines, and growth factors (52).”
BackgroundInfluentialmTOR as a senescence manipulation target: A forked road
Saoudaoui, S., Bernard, M., Cardin, G. B., Malaquin, N., Christopoulos, A., & Rodier, F. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.02.002 · Cited by 38
Self-citationMetabolic remodeling in cancer and senescence and its therapeutic implications
Kim, Y., Jang, Y., Kim, M.-S., & Kang, C. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.008 · Cited by 36
Exosomal long noncoding RNAs in aging and age‐related diseases
Cao, Q., Guo, Z., Yan, Y., Wu, J., & Song, C. (2019) · IUBMB Life · doi:10.1002/iub.2141 · Cited by 36
“Cell senescence is mainly controlled by the p53/p21 and p16/retinoblastoma protein pathways and is characterized by permanent stagnation of cell proliferation, accompanied by morphological and functional changes, including an enlarged and flattened cell morphology, agingrelated β-galactosidase activation, and heteroch…”
BackgroundKarpuzoglu, E., Holladay, S. D., & Gogal, R. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1704203 · Cited by 65
Cellular senescence and neurodegeneration
Holloway, K., Neherin, K., Dam, K. U., & Zhang, H. (2023) · Human Genetics · doi:10.1007/s00439-023-02565-x · Cited by 43
At the stem of youth and health
Beltrami, A. P., Cesselli, D., & Beltrami, C. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.10.005 · Cited by 39
“…cells or even distal cells within tissues (Shelton et al., 1999), thus stimulating chronic tissue remodeling and/or local inflammation; this characteristic feature of senescent cells has been termedsenescence-associated secretoryphenotype (SASP, seediscussion later) (Coppe et al., 2008).”
BackgroundConod, A., Silvano, M., & Altaba, A. R. I. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110490 · Cited by 36
Cellular senescence and hepatitis B‐related hepatocellular carcinoma: An intriguing link
Karakousis, N. D., Papatheodoridi, A. M., Chatzigeorgiou, A., & Papatheodoridis, G. (2020) · Liver International · doi:10.1111/liv.14659 · Cited by 38
The Molecular Intersection Between Senescence and Major Depression in the Elderly
Diniz, B. S. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.07.005 · Cited by 39
Ré, R. N., & Cook, J. L. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00414.2009 · Cited by 36
Lehmann, J., Narcisi, R., Franceschini, N., Chatzivasileiou, D., Boer, C. G., Koevoet, W. J. L. M., Putavet, D. A., Drabek, D., van Haperen, R., de Keizer, P. L. J., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04035-x · Cited by 40
“e Gene set enrichment analysis for sets of SASP genes [11] cell cycle associated genes [44], DNA repair associated genes [45] and size-matched set of random genes with normalized enrichment score (NES) and multiple-testing adjusted (Holms–Bonferroni) p values given.”
BackgroundMethodVamvakas, S. M., Mavrogonatou, E., & Kletsas, D. (2017) · European Spine Journal · doi:10.1007/s00586-017-5198-0 · Cited by 36
Cellular senescence and senescence‐associated T cells as a potential therapeutic target
Nakagami, H. (2020) · Geriatrics & Gerontology International · doi:10.1111/ggi.13851 · Cited by 35
Vonbrunn, E., Mueller, M., Pichlsberger, M., Sundl, M., Helmer, A., Wallner, S. A., Rinner, B., Tuca, A., Kamolz, L., Brislinger, D., et al. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.604123 · Cited by 35
“…wounds, which are characterized by prolonged and sub-optimal inflammation, concurrent infection, deregulation of proteases (Eming et al., 2010), reduced growth factor activity (Lauer et al., 2000), stem cell dysfunction (Stojadinovic et al., 2014), and cellular senescence (Coppé et al., 2008).”
BackgroundKrause, G. J., Diaz, A., Jafari, M., Khawaja, R. R., Agullo‐Pascual, E., Santiago‐Fernández, O., Richards, A. L., Chen, K., Dmitriev, P., Sun, Y., et al. (2022) · Aging Cell · doi:10.1111/acel.13713 · Cited by 35
“To avoid the confounding effect of elevated secretion in cellular senescence (Coppé et al., 2008), we only used early passage cultures, which we previously confirmed contained less than 1% of senescent cells (positive for β- galactosidase) (Bejarano et al., 2018).”
MethodRiviere-Cazaux, C., Carlstrom, L. P., Neth, B. J., Olson, I., Rajani, K. R., Rahman, M., Ikram, S., Mansour, M. A., Mukherjee, B., Warrington, A. E., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00476-8 · Cited by 39
“SASP factors include cytokines and chemokines such as IL-6 21 , IL-8 22 , and MIP-3 α 23 , in addition to growth factors 24 and matrix metallopro-teases 25,26 .”
BackgroundInfluentialImmunosenescence: A Critical Factor Associated With Organ Injury After Sepsis
Lü, X., Yang, Y.-M., & Lu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.917293 · Cited by 37
“In addition to detecting aging markers, p16, p21, and SASP in the liver, kidneys, lungs, and other solid organs of immunosenescent mice, tissue damage is also observed in these organs.”
BackgroundInfluentialKotla, S., Zhang, A., Imanishi, M., Ko, K. A., Lin, S. H., Gi, Y. J., Moczygemba, M. M., Isgandarova, S., Schadler, K., Chung, C. D., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102132 · Cited by 40
Biliary Epithelial Senescence in Liver Disease: There Will Be SASP
Meadows, V., Baiocchi, L., Kundu, D., Sato, K., Fuentes, Y., Wu, C., Chakraborty, S., Glaser, S. S., Alpini, G. D., Kennedy, L. L., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.803098 · Cited by 38
“Two other specific features belong to a senescent cell: 1) lack of progression toward apoptosis; and 2) development of a SASP (Coppé et al., 2008).”
BackgroundImplications of inflammatory states on dysfunctional immune responses in aging and obesity
Thomas, A. L., Alarcon, P. C., Divanovic, S., Chougnet, C. A., Hildeman, D. A., & Moreno-Fernandez, M. E. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.732414 · Cited by 35
“, IL-6, Interleukin-1 [IL-1] and colony stimulating factor [CSF]) (Garfinkel et al., 1994; Coppé et al., 2008), thus their accumulation might be directly responsible for systemic increases in inflammatory proteins with age.”
BackgroundAging: past, present and future
Blagosklonny, M. V., Campisi, J., & Sinclair, D. A. (2009) · Aging · doi:10.18632/aging.100009 · Cited by 35
Self-citationContribution of viral and bacterial infections to senescence and immunosenescence
Reyes, A., Ortiz, G., Duarte, L. F., Fernández, C., Hernández‐Armengol, R., Palacios, P. A., Prado, Y., Andrade, C. A., Rodríguez‐Guilarte, L., Kalergis, A. M., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1229098 · Cited by 39
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.